Corcept Therapeutics (NASDAQ:CORT) Announces Earnings Results, Misses Estimates By $0.13 EPS

Corcept Therapeutics (NASDAQ:CORT) issued its earnings results on Tuesday. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.13), FiscalAI reports. Corcept Therapeutics had a net margin of 14.19% and a return on equity of 15.99%. The business had revenue of $202.13 million for the quarter, compared to the consensus estimate of $254.94 million. During the same period in the previous year, the firm earned $0.26 EPS. The company’s revenue was up 11.1% compared to the same quarter last year.

Here are the key takeaways from Corcept Therapeutics’ conference call:

• Corcept reported 2025 revenue of $761 million (up from $675M) and provided 2026 revenue guidance of $900 million–$1 billion, driven primarily by its Cushing’s syndrome business.
• The FDA issued a complete response letter denying approval of relacorilant for Cushing’s syndrome; the company plans an April meeting with FDA and intends to appeal, resubmit, or possibly run a new study — creating regulatory uncertainty and potential delays.
• The Phase 3 ROSELLA trial in platinum‑resistant ovarian cancer met both primary endpoints, showing a 35% reduction in risk of death (HR 0.65, p=0.0004) and a 4.1‑month median OS benefit; Corcept expects an oncology PDUFA date of July 11 and foresees rapid adoption if approved.
• Demand for Korlym surged in 2025 (37% more tablets; record new prescriptions and prescribers); prior specialty pharmacy capacity issues are being resolved after a vendor transition, and management expects continued commercial growth (targeting at least $2 billion annual Cushing revenue by decade end).
• The pipeline advanced: a Phase 2b MASH study (MONARCH) is fully enrolled with results due by year‑end, and ALS data (DASLES) showed an 84% reduction in risk of death (p=0.0009), prompting a planned pivotal trial after addressing GI tolerability via dose‑titration work.

Corcept Therapeutics Trading Up 3.2%

Shares of Corcept Therapeutics stock opened at $36.48 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.14 and a quick ratio of 3.07. Corcept Therapeutics has a 1 year low of $28.66 and a 1 year high of $117.33. The firm has a market cap of $3.84 billion, a PE ratio of 41.46 and a beta of 0.25. The company has a 50 day simple moving average of $47.21 and a two-hundred day simple moving average of $66.45.

Insider Activity at Corcept Therapeutics

In other Corcept Therapeutics news, insider Sean Maduck sold 20,000 shares of the firm’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $79.52, for a total transaction of $1,590,400.00. Following the sale, the insider owned 7,904 shares in the company, valued at $628,526.08. This trade represents a 71.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Joseph Douglas Lyon sold 5,000 shares of Corcept Therapeutics stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $79.53, for a total value of $397,650.00. Following the sale, the insider directly owned 10,277 shares of the company’s stock, valued at approximately $817,329.81. This trade represents a 32.73% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 125,000 shares of company stock worth $8,301,450. Corporate insiders own 20.50% of the company’s stock.

Institutional Investors Weigh In On Corcept Therapeutics

A number of hedge funds have recently made changes to their positions in CORT. Advisory Services Network LLC bought a new stake in Corcept Therapeutics in the third quarter worth $25,000. Atlas Capital Advisors Inc. purchased a new position in shares of Corcept Therapeutics in the fourth quarter worth about $31,000. Larson Financial Group LLC lifted its stake in shares of Corcept Therapeutics by 2,326.3% in the 3rd quarter. Larson Financial Group LLC now owns 461 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 442 shares during the last quarter. Gould Capital LLC boosted its holdings in Corcept Therapeutics by 50.0% during the 3rd quarter. Gould Capital LLC now owns 600 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 200 shares during the period. Finally, CIBC Private Wealth Group LLC grew its position in Corcept Therapeutics by 128.5% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 770 shares of the biotechnology company’s stock worth $64,000 after acquiring an additional 433 shares during the last quarter. 93.61% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on CORT. Truist Financial set a $50.00 price objective on Corcept Therapeutics in a report on Wednesday, December 31st. Zacks Research cut Corcept Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Tuesday, January 13th. UBS Group began coverage on shares of Corcept Therapeutics in a report on Tuesday, December 16th. They issued a “neutral” rating and a $95.00 price target on the stock. Canaccord Genuity Group boosted their price objective on shares of Corcept Therapeutics from $99.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, January 23rd. Finally, Wolfe Research cut shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $30.00 target price on the stock. in a research note on Wednesday, December 31st. Four equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $77.17.

Key Stories Impacting Corcept Therapeutics

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Company issued audited Q4 and full‑year 2025 results and an optimistic outlook that management characterized as positive for the business — this messaging likely supports intraday buying interest. Corcept Therapeutics Posts Strong 2025 Results
• Neutral Sentiment: Company updated FY‑2026 revenue guidance to a $900 million – $1.0 billion range; the midpoint sits slightly below some sell‑side consensus, leaving room for mixed analyst reactions and uncertainty about near‑term estimates. FY‑2026 Guidance / Press Release
• Negative Sentiment: Reported Q4 EPS of $0.20 missed consensus ($0.27) and revenue of ~$202.1M missed estimates (~$254.9M). The beat/miss details explain part of today’s volatility and investor caution. Earnings Details / Conference Call
• Negative Sentiment: Multiple law firms have filed or are soliciting lead‑plaintiff applicants in a securities class action covering Oct. 31, 2024–Dec. 30, 2025, alleging Corcept failed to disclose FDA concerns about the adequacy of evidence for the relacorilant NDA — this legal overhang is materially negative and has been cited as a driver of a prior ~50% share decline. Representative notices: Robbins LLP and Rosen Law Firm. Robbins LLP Class Action Notice Rosen Law Firm Notice
• Negative Sentiment: Analyst reaction: HC Wainwright cut its price target (reflecting changed expectations post‑NDA/FDA disclosure), adding downward pressure on sentiment. HC Wainwright PT Cut

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.